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Among breast cancer subtypes, basal-like breast cancer is particularly aggressive, and 
research on the molecules involved in its pathology might contribute to therapy. In this 
study, we found that expression of NKX6.1, a homeobox transcription factor, is higher 
in basal-like breast cancer than in other subtypes. In loss-of-function experiments on 
basal-like breast cancer cell lines, NKX6.1-depleted cells exhibited reduced cell growth. 
Because cytokine interleukin-6 (IL-6) is expressed in basal-like breast cancer, and 
increases cell growth, we analyzed expression levels of IL6, an IL-6 gene, and observed 
reduced IL6 expression in NKX6.1-depleted cells. In a reporter assay, IL6 promoter 
activity was reduced by loss of NKX6.1 function. A pull-down assay showed that 
NKX6.1 binds to the proximal region in IL6 promoter. These results indicate that 
NKX6.1 directly up-regulates IL6 expression. To investigate further, we established 
cells with forced expression of IL-6. We observed that exogenous IL-6 expression 
restored the reduced cell growth of NKX6.1-depleted cells. Furthermore, orthotopic 
xenografts showed that NKX6.1-depleted cells lost the capacity for tumor formation. 
We therefore conclude that NKX6.1 is a factor for IL-6-regulated growth and tumor 
formation in basal-like breast cancer. Our findings facilitate profound understanding of 
basal-like breast cancer, and the development of suitable therapy. 
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Breast cancer is the most common cancer in women [1]. It is classified into five 
subtypes, based on differences in gene expression patterns: luminal A; luminal B; 
human epidermal growth factor receptor 2 (HER2)-enriched; normal breast-like; and 
basal-like [2]. Among these, basal-like breast cancer is particularly aggressive, with the 
worst prognosis [3]. 
Basal-like breast cancer is characterized by the strong expression of basal 
markers such as cytokeratin 5/6 and 17 [2, 4, 5]. It is associated with up-regulation of 
mesenchymal markers, such as vimentin, smooth muscle actin, and N-cadherin, and 
reduced expression of epithelial markers, such as E-cadherin [6-8]. 
Transcription factors determine and maintain cellular characteristics through 
regulation of gene expression. Some transcription factors have been identified and 
analyzed with the aim of improving our understanding of the nature of basal-like breast 
cancer [9-12]. Although we now know about this cancer’s molecular properties, we do 
not yet fully understand it, and the transcription factors responsible for basal-like breast 
cancer pathology still remains to be identified and investigated. 
NKX homeobox protein is a family of transcription factors that possess a DNA 
binding domain [13], which amino acid sequence is conserved among family members. 
The NKX family of genes has been found to play a role in various types of cancer. For 
example, NKX2.1 functions as a proto-oncogene, and is closely associated with lung 
cancer [14-16]. NKX2.8 expresses in liver cancer, and regulates the expression of 
α-Fetoprotein, a fetal oncogene [17]. Loss of NKX3.1 function is an initiating event in 
prostate carcinogenesis [18]. NKX6.1 is a metastasis suppressor that regulates the 
epithelial-mesenchymal transition in cervical cancer [19]. With respect to breast cancer, 
some studies of the role of NKX family members in luminal breast cancer have been 
conducted [20, 21], but none have focused on the basal-like type. Given that NKX 
family members are involved in the pathologic functions of various cancers, it is 
reasonable to surmise that there might be as yet unrecognized NKX factor(s) active in 
basal-like breast cancer. 
Interleukin-6 (IL-6) is a cytokine that plays a role in various biological activities, 
including cell growth and differentiation. In basal-like breast cancer, the level of IL-6 
secretion is high, and the IL-6/Janus kinase (JAK) 2/signal transducer and activator of 
the transcription 3 (STAT3) pathway is active in regulating cell growth [22, 23]. In this 
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pathway, IL-6 binds to IL-6 receptor and activates JAK2 tyrosine kinase. Activated 
JAK2 proteins facilitate phosphorylation of STAT3. Phosphorylated-STAT3 (pSTAT3) 
is then translocated into the nucleus to regulate genes involved in apoptosis and 
proliferation. The IL-6/JAK2/STAT3 signaling pathway is therefore a potential target 
for cancer therapy [24-27].  
Since IL6, an IL-6 gene, expression is involved in breast cancer cell growth, 
some studies have focused on the regulation of IL6 expression in these cells. The 
epigenetic status of IL6 expression differs between IL6-low luminal and IL6-high 
basal-like breast cancer cells [28]. The IL6 promoter of basal-like breast cancer is 
demethylated, and this epigenetic activation is regulated by the IL-6 autocrine loop [29]. 
In luminal breast cancer, estrogen receptor, a nuclear receptor, inhibits IL6 expression 
[30]. However, specific regulators for IL6 expression in basal-like breast cancer have 
not been fully understood. 
In this study we found that expression of NKX6.1, also known as NKX6A, is 
up-regulated in basal-like breast cancer, compared to other breast cancer subtypes. We 
show that NKX6.1 regulates IL6 expression by binding to the IL6 promoter to promote 
cell growth. In addition, NKX6.1 is involved in tumor formation. These results improve 
our understanding of basal-like breast cancer pathology, and might contribute to future 
therapy for this type of cancer. 
 
2. Materials and methods 
2.1 Cell culture and animal experiment 
The breast cancer cell lines MCF10A, MCF-7, T-47D and MDA-MB-231 were 
obtained from American Type Culture Condition (Manassas, VA, USA). SUM159 cells 
were obtained from Asterand (Detroit, MI, USA). The colon cancer cell lines HCT116 
and LoVo were obtained from RIKEN BioResource Center (Tsukuba, Japan).  
MCF10A cells were maintained with DMEM/F12 containing 5% horse serum, 
50 μg/mL EGF, 500 ng/mL hydrocortisone, 100 ng/mL cholera toxin and 10μg/mL 
insulin. MCF-7 cells were cultured with RPMI-1640 medium containing 1 nM estradiol 
and 10% fetal bovine serum (FBS). T-47D and MDA-MB-231 cells were cultured with 
RPMI-1640 containing 10% FBS. HCT116 cells were cultured with DMEM containing 
10% FBS. SUM159 cells were maintained in Ham’s F-12 nutrient mixture containing 
5% FBS, 5 μg/mL insulin, 1 μg/mL hydrocortisone and 10 mM HEPES. LoVo cells 
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were maintained with Ham’s F-12 nutrient mixture containing 10% FBS. In drug 
selection for infectants, 1 μg/mL puromycin or 10 μg/mL blasticidin S was used. For 
the xenograft assay, 1 × 106 cells were suspended in 40 μL of serum-free medium, 
mixed with equal amount of Matrigel (Corning, 356237, Bedford, MA, USA), and 
transplanted into the mammary fat pad of six-week-old NOD/SCID mice. In the same 
mouse, control and NKX6.1 knockdown cells were injected at the right and the left 
sides, respectively. The animal experiments in this study were approved by the Animal 
Research Committee of Kyoto University. All animals were maintained according to the 
Guide for the Care and Use of Laboratory Animals (National Institute of Health 
Publication). 
 
2.2 Quantification of mRNA level 
The primers used in this study are listed in Supplementary Table S1. For RNA-seq 
analysis and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
analysis, RNA samples were extracted using TRIzol (Life Technologies, 15596026, 
Carlsbad, CA, USA) and PureLink RNA micro kits (Life Technologies, 12183-016). 
For RNA-seq analysis, total RNA samples from 3 independent extractions were pooled, 
and used for a cDNA library for analysis with HiSeq2500 system (Illumina, San Diego, 
CA, USA). Aligned data was normalized by RPKM method [31] and quantified with 
Strand NGS software (Strand Life Sciences, Aurora, CO, USA). For each qRT-PCR 
sample, 1 μg of total RNA was used for cDNA synthesis with SuperScript III (Life 
Technologies, 18080051). A 1:10 dilution of synthesized cDNA solution was used as 
the template in each qRT-PCR reaction with FastStart Universal SYBR Green Master 
(Roche, 04913850001, Mannheim, Germany). The StepOne Plus Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA) was used to run the qRT-PCR 
analyses. Amplification of EF1A1 was used as an internal control. The following 
conditions were used: 95 °C for 10 min, then 40 cycles of 95 °C for 15 s, 60 °C for 30 s 
and 72 °C for 1 min. The relative mRNA levels and standard deviations were calculated 
according to the manufacturer’s instructions. The cycle threshold value normalized by 
the EF1A1 value was used for statistical analysis. 
 
2.3 Immunoblotting 
Rabbit anti-NKX6.1 antibody (1:500; Sigma, HPA036774, St. Louis, MO, USA), rabbit 
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anti-phospho-STAT3 Tyr705 (D3A7) antibody (1:1000; Cell Signaling technology, 
X9145, Danvers, MA, USA), rabbit anti-STAT3 (D3Z2G) antibody (1:1000; Cell 
Signaling Technology, 12640), rabbit anti-IL-6 antibody (1:1000; Cell Signaling 
Technology, 12153), rabbit anti-FLAG antibody (1:500; Sigma, F7425) and mouse 
anti-beta actin antibody (1:5000; Abcam, ab6276) were used for primary reactions. The 
Easy-Western-II detection system (Beacle, BCL-EZS21, Kyoto, Japan) was used 
instead of secondary antibody for rabbit IgG. We used goat anti-mouse IgG antibody 
conjugated to a peroxidase (1:50,000; Pierce biotechnology, 31340, Rochford, IL, USA) 
to detect beta-actin signals. Images were obtained with Ez-Capture II (ATTO, Tokyo, 
Japan) and ImageSaver5 Software (ATTO). 
 
2.4 Construction of plasmid vectors 
For NKX6.1 knockdown, we constructed an shRNA expression system. We used a 
lentiviral vector, pLKO.1 (Addgene, 8453), which has the human U6 promoter. The 
sequences of shRNAs are listed in Supplementary Table S2. To knockout the NKX6.1 
gene, we used a lentiviral vector for the CRISPR/Cas9 system, lentiCRISPR v2 
(Addgene, 52961). The target sequence for GFP control is 
5’-CAACGTCTATATCATGGCCG-3’, and that for NKX6.1 knockout is 
5’-TGGGCCGGTACCCCAAGCCG-3’. 
To construct a FLAG-tagged gene, we inserted a synthesized double strand oligo, 
5’-CACCATGGGCGGCGGCGGCTCCGACTACAAGGACGACGACGACAAGTGA
-3’, into the cloning site of pENTR vector (Life Technologies, K2400-20, USA). The 
inserted sequence has an NcoI site, a GGGGS linker-FLAG coding sequence and an 
opal terminator. We cloned the IL6 cDNA into the NcoI site using the In-Fusion HD 
cloning system (Takara Bio, Z9645N, Otsu, Japan). We then subcloned the FLAG or 
IL6-FLAG gene into the lentiviral vector, pLenti 6.3 (Life Technologies, V533-06). 
To analyze IL6 promoter activity, we cloned a fragment of the upstream region 
of the IL6 transcription start site into the upstream region of the minimal promoter 
(miniP) of the pGL4.30 vector (Promega, Madison, WI, USA). The IL6 promoter-miniP 
fragment was subcloned into the region between the ClaI - SpeI sites of the pLenti 6.3 
vector. Mutations were introduced by In-Fusion system (Takara).  
 
2.5 Growth assay 
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Cells were plated in 24-well plates at a density of 5 × 104 cells/well on day 0. On day 4, 
cells were trypsinized and resuspended in the medium as single cells. Four samples 
were collected from each well, and each sample was mixed with the same quantity of 
trypan blue solution. Viable cells were counted manually under a microscope. We 
calculated the mean of the four samples from each well as the cell number for that well, 
and analyzed four wells for each experimental group. 
 
2.6 Immunostaining 
For immunostaining, cells were cultured in chamber slides and fixed by 2% 
paraformaldehyde in PBS for 20 min at room temperature. For permeabilization, cells 
were treated with 0.1% Triton X-100 in PBS for 10 min. The primary antibodies we 
used were rabbit anti-NKX6.1 antibody (1:500; Sigma, HPA036774), rabbit 
anti-phospho-STAT3 Tyr705 (D3A7) antibody (1:100; Cell Signaling Technology, 
X9145), monoclonal anti-FLAG M2 antibody (1:1000; Sigma, F1804), and proliferating 
cell nuclear antigen (PCNA) (1:10; Dako, M0879 clone PC10, Glostrup, Denmark). The 
secondary antibody were goat anti-rabbit IgG antibody conjugated with Alexa Fluor 
546 (1:1000; Life Technologies, A11010) and goat anti-mouse IgG antibody conjugated 
with Alexa 488 (1:1000; Life Technologies, A11001). Hoechst 33342 (1:1000; Dojindo, 
346-07951, Kamimashiki, Japan) was used for counter staining. 
TUNEL assay was performed using an In Situ Cell Death Detection Kit 
(Roche, 11684817910). Cells in chamber slides were fixed using 2% paraformaldehyde 
in PBS for 30 min at room temperature. After washing with PBS, fixed cells were 
permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate solution for 2 min on ice. 
Samples were then washed, and incubated with TUNEL reaction mixture for 2 h at 
37°C. Goat anti-Fluorescein / Oregon Green antibody conjugated with Alexa Fluor 488 
(1:1000; Life Technologies, A11096) was used to visualize the TUNEL signal, and 
Hoechst 33342 (1:1000) was used for counter staining. PCNA- and TUNEL-positive 
cells were counted manually in 1.5 mm2 region in each staining. 
 
2.7 Luciferase assay 
To analyze the effect of NKX6.1 knockdown on IL6 promoter, 2 × 104 cells containing 
IL6 promoter reporter were seeded in a 96-well plate. Luciferase activity was measured 
on the second day after cell seeding using the Luciferase Reporter Assay System 
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(Promega, E2920). Luciferase activity was measured using the GloMax-Multi Detection 
System (Promega). 
 
2.8 Pull-down assay 
Cells were cultured in two 10 cm dishes and harvested at 70–80% confluence by adding 
500 μL binding buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM MgCl2, 0.5% 
NP-40, 5% Glycerol) containing the protease inhibitor cocktail COMPLETE (Roche), 
and frozen at –80 °C. They were thawed at 37 °C for 10 min, then briefly sonicated. For 
the pull-down assay, we used Dynabeads MyOne Stretavidin T1 (Life Technologies, 
65602) magnetic beads. The beads were blocked with 20 mg/mL BSA and 100 μg/mL 
salmon sperm DNA. We mixed 1.2 mg of beads with 50 pmol of biotinylated oligos, 
and incubated the mixture for 10 min at room temperature. We then added 100 μL of 
cell lysate and incubated the mixture for 30 min at 4 °C with or without competitor 
oligos. Samples were washed four times in 1 mL binding buffer, and the bound 
molecules were eluted with sample buffer. 
 
2.9 Chromatin immunoprecipitation (ChIP) assay 
ChIP assay was performed using a SimpleChIP Plus Enzymatic Chromatin IP Kit 
(Magnetic Beads) (Cell Signaling Technology, 9005), according to the manufacturer’s 
protocol, with monoclonal anti-FLAG M2 antibody (10 μL; Sigma, F7425). ChIP 
eluents were analyzed using quantitative PCR and regular PCR with primers targeting 
the proximal region in the IL6 promoter (Table S1). 
 
2.10 Electrophoretic mobility shift assay (EMSA) 
EMSA was performed using 25 bp fragments of the IL6 promoter having either the 
wide type or mutated sequence (Table S3). Fifteen microliters of SUM159 cell lysates, 
prepared as described above (section 2.8), were incubated with 50 pmol DNA fragments 
in a binding buffer (10mM Tris-HCl (pH7.5), 1 mM Na2EDTA (pH8), 50 mM KCl, 5 
mM CaCl2, 3 mM MgCl2, 5% glycerol and 0.05% Nonidet P-40) for 10 min at 37 °C. 
After incubation, samples were electrophoresed with 6% polyacrylamide gel in 0.5 × 
TBE buffer to separate the reaction batches. The gel was stained with ethidium bromide, 





2.11 Statistical analysis 
The qRT-PCR, cell growth, and luciferase assay results were analyzed using Student’s 
t-test. Fisher’s exact test was used to analyze differences in tumor formation ratios. 
Gene Expression Omnibus data was analyzed using Mann-Whitney U test. Statistical 





3.1 NKX6.1 expression is up-regulated in basal-like breast cancer cells 
NKX homeobox genes have been implicated in a wide variety of biological events, 
including cancer [14-21, 32]. To identify NKX factors for basal-like breast cancer, we 
performed expression screening of the NKX family of genes using qRT-PCR. We used 
the following human breast cancer cell lines: a non-tumorigenic cell line, MCF10A; two 
luminal cell lines, MCF-7 and T-47D; and two basal-like cell lines SUM159 and 
MDA-MB-231. We observed detectable amplification of six out of 14 NKX gene 
family members: NKX1.2, NKX2.1, NKX2.8, NKX3.1, and NKX6.1 (Fig. 1A–E). 
We express the mRNA levels for each gene as relative to the mean level in 
MCF-7 cells, which we define as 1. NKX1.2 expression was higher in T-47D cells than 
in other cells (Fig. 1A). NKX2.1 was not detected in MCF10A or SUM159 cells (Fig. 
1B). In comparison with MCF-7 cells, NKX2.8 expression was high in T-47D and 
MDA-MB-231 cells, and low in SUM159 cells (Fig. 1C). No remarkable difference of 
the NKX3.1 level was observed (Fig. 1D). Unlike the other NKX family members, the 
NKX6.1 expression was strongly up-regulated in basal-like breast cancer cell lines (Fig. 
1E). 
To analyze levels of NKX6.1 protein in breast cancer cell lines, we performed 
immunoblotting using anti-NKX6.1 antibody. We observed NKX6.1 signals in 
SUM159 and MDA-MB-231 cells, but not in MCF10A, MCF-7, or T-47D cells (Fig. 
1F). We also performed immunostaining of NKX6.1 in these 5 cell lines and observed 
NKX6.1 signals in the nuclei of SUM159 and MDA-MB-231 cells, indicating that 
NK6.1 localizes in the nucleus, however, no signal was observed in the other 3 cell lines 
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(Fig. 1G-K). The results of immunblotting and immustaining suggest that NKX6.1 
protein level is increased in basal-like breast cancer cell lines. 
A dataset of basal-like breast cancer patients, GSE3744 [33], is available in the 
public gene expression database, Gene Expression Omnibus. In this dataset, 47 clinical 
samples (18 basal-like tumors and 29 others, including normal breast and non basal-like 
breast tumors) were included. RNA samples were extracted from tissue samples, and 
expression data were obtained using Affymetrix Human Genome U133 Plus 2.0 Arrays 
[33]. We used Mann-Whitney U test to analyze difference in NKX6.1 level between 
basal-like and others. The result showed that NKX6.1 expression is significantly higher 
in patients with basal-like breast cancer than in patients with normal breasts or other 
types of breast cancer (Fig. S1). NKX6.1 expression is thus high in basal-like breast 
cancer both in vitro and in vivo. 
 
3.2 NKX6.1 contributes to the growth of basal-like breast cancer cells 
To analyze the functions of NKX6.1, we constructed an shRNA expression system for 
NKX6.1. We used shGFP as a control. We introduced shRNA constructs into the 
basal-like breast cancer cell lines, SUM159 and MDA-MB-231. In both SUM159 and 
MDA-MB-231 cells, the NKX6.1 mRNA level was significantly reduced in knockdown 
cells relative to the shGFP control group (Fig. 2A). Immunoblotting confirmed the 
reduction of NKX6.1 levels in knockdown cells (Fig. 2B). When we cultured NKX6.1 
knockdown cells, reduced cell growth was observed. Therefore we analyzed cell growth 
by counting cell number. In the results, cell growth was significantly reduced in both 
the SUM159 and MDA-MB-231 cell lines (Fig. 2C,D). 
Since an shRNA-mediated knockdown system has an off-target effect, it is 
necessary to validate the result via another loss-of-function system. We used a 
CRISPR/Cas9 system for this purpose [34, 35]. We established a 
CRISPR/Cas9-mediated NKX6.1 knockout cell line (crNKX6.1) in the MDA-MB-231 
cells. CRISPR/Cas9 for GFP was constructed as a control (crGFP). We used 
immunoblotting to test whether NKX6.1 had been knocked out. Because the epitope 
region for the antibody used is upstream of our CRISPR target region, there was a 
truncated NKX6.1 signal in the crNKX6.1 cells (Fig. 2E). Because of an amino acid 
homology with the homeodomain of the NKX factors [36, 37], the truncated NKX6.1 
lacked the homeodomain, implying that it was not able to bind to DNA, and to regulate 
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gene expression. To analyze its localization, we constructed cells with forced expression 
of intact NKX6.1-FLAG and truncated NKX6.1-FLAG, and conducted immunostaining 
with anti-FLAG antibody. We observed FLAG signals in the nuclei of SUM159 and 
MDA-MB-231 cells with forced expression of intact NKX6.1-FLAG. However, in cells 
with truncated NKX6.1-FLAG, FLAG signals were distributed to the cytoplasm, 
suggesting that truncated NKX6.1 has lower gene-regulation ability (Fig. S2). 
In the cell proliferation assay, cell growth was significantly reduced in 
crNKX6.1 cells relative to their parental MDA-MB-231 and the crGFP cells (Fig. 2F). 
Thus both the shRNA-mediated knockdown and CRISPR/Cas9-mediated knockout 
systems displayed a reduction in cell growth, indicating that NKX6.1 promotes cell 
growth in basal-like breast cancer. 
Next, we determined whether the reduction in cell number caused by NKX6.1 
suppression was the result of cell cycle arrest, reduced cell survival, or both. To 
quantitatively analyze cell proliferation and cell death, we used PCNA staining and 
TUNEL assay, respectively (Fig. 2G,H, and S3). The percentage of PCNA-positive 
cells in the NKX6.1 loss-of-function group was significantly smaller than in the control 
group (Fig. 2G,H). In TUNEL assay, cells with NKX6.1 knockdown showed an 
increased percentage of TUNEL-positive cells, but no significant change was observed 
in NKX6.1 knockout cells (Fig. S3). This indicates that the reduced cell survival 
observed in NKX6.1 knockdown cells is an off-target effect. We therefore conclude that 
NKX6.1 promotes cell proliferation. 
Since basal-like breast cancer features mesenchymal gene expression, and 
NKX6.1 acts as a regulator for epithelial and mesenchymal gene transcription in 
cervical cancer [19]. We analyzed changes in mRNA levels of an epithelial marker, 
CDH1, and mesenchymal markers, VIM and CDH2. CDH1, an E-cadherin gene, was 
not detected in either the SUM159 or the MDA-MB-231 cells. Expression of VIM, a 
vimentin gene, and CDH2, an N-cadherin gene, was not significantly affected by 
NKX6.1 knockdown or knockout (Fig. S4). This suggests that NKX6.1 is not involved 
in maintenance of mesenchymal status in basal-like breast cancer. 
 
3.3 NKX6.1 up-regulates IL6 expression in basal-like breast cancer cells 
Since NKX6.1 is a transcription factor, it must control the expression of a gene(s) 
involved in cell growth. To identify NKX6.1-regulatd genes, RNA-seq analysis was 
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performed in SUM159 cells. We searched genes involving cell proliferation based on 
gene ontology, and obtained candidate genes (Supplementary Table S4). Among these 
candidates, this study focused on IL6, the gene encoding the IL-6 protein, because 
secretion of IL-6 is high in basal-like breast cancer, where it exhibits a paracrine effect 
to positively regulate cell growth [22, 23, 28]. We measured IL6 mRNA levels in 
NKX6.1 knockdown and knockout cells by qRT-PCR. In both cell types, IL6 expression 
was significantly reduced (Fig. 3A,B), indicating that NKX6.1 up-regulates IL6 
expression in basal-like breast cancer. 
IL-6 is a signaling molecule that activates the JAK2/STAT3 pathway by binding 
to its receptors [24]. pSTAT3 is used as a marker for the activation of IL-6 signaling. In 
our control group, immunostaining with anti-pSTAT3 antibody showed that most cells 
were pSTAT3-positive, while both the SUM159 and MDA-MB-231 shNKX6.1 cells 
displayed a weak pSTAT3 signal (Fig. 3C–F). Immunoblotting showed that pSTAT3 
levels were reduced following NKX6.1 knockdown, although the total quantity of 
STAT3 was not affected (Fig. 3G). This suggests that NKX6.1 supports IL-6 signaling 
through the up-regulation of IL6 expression. 
 
3.4 NKX6.1 activates IL6 promoter 
Next, we determined whether NKX6.1 directly stimulates IL6 promoter activity 
utilizing a luciferase reporter system. We connected different lengths of upstream 
regions from the IL6 transcription start site to a minimal promoter (Fig. S5A). We 
subcloned them into lentiviral vectors containing the firefly luciferase gene, and 
established IL6 promoter reporter cell lines via lentiviral-mediated gene transfer. A 
construct containing a constitutive promoter, cytomegalovirus (CMV) immediate early 
promoter, was used as a control. To analyze whether NKX6.1 is involved in IL6 
promoter activity, we knocked-down NKX6.1 expression in these reporter cell lines and 
measured luciferase activity (Fig. S5B,C). Promoter activity was significantly reduced 
relative to the control in each construct, in all cells except those with a 20 bp fragment 
(Fig. 4A,B). This indicates that NKX6.1 up-regulates IL6 expression by activating the 
IL6 promoter. 
In the cells containing a proximal 20 bp fragment, there was a small amount of 
promoter activity (Fig. S5B,C), which was not affected by NKX6.1 knockdown (Fig. 
4A,B). This indicates that NKX6.1 does not activate this 20 bp region. The activity of 
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cells with the 20 bp fragment was less even than the reduced activity of the NKX6.1 
knockdown cells with the longer fragments, suggesting that the 20 bp region lacks the 
sequences necessary to respond to some transcription factors, including NKX6.1. 
A transcription factor binds to DNA to regulate gene expression. To analyze the 
binding potential of NKX6.1 to the IL6 promoter region, we performed a pull-down 
assay using 100 bp fragments from the region upstream of the IL6 transcription start site. 
NKX6.1 did bind to this 100 bp fragment (Fig. 4C). In competitor assays using the 
proximal 100 bp, 50 bp, and 20 bp fragments, NKX6.1 binding was blocked by the 100 
bp and 50 bp fragments but not by the 20 bp fragment (Fig. 4D). We can therefore 
conclude that NKX6.1 binds to the promoter region of the IL6 gene and activates IL6 
expression.  
To confirm that NKX6.1 binds to the IL6 promoter region in living cells, we 
performed ChIP assay. We established SUM159 cells with forced expression of 
NKX6.1-FLAG. FLAG-expressing cells were used as a control. Anti-FLAG antibody 
was used for precipitation. In the results of PCR analyses of the IL6 promoter region in 
precipitated samples, we observed enrichment of the region in NKX6.1-FLAG samples 
(Fig. 4E, F). The results indicate that NKX6.1 directly binds to the IL6 promoter region 
in living cancer cells. 
 Previous study has reported that NKX6.1 binds to A/T-rich sequence flanked 
by G/C residues [38]. We found two candidate sequences, site1 and site2, in the region 
between 50 bp and 20 bp (Fig. 4G). To identify NKX6.1-response site, we mutated the 
sequence of each candidate site in the reporter having 50 bp fragment (Mut1 and Mut2 
shown in Fig. 4G). We knocked-down NKX6.1 expression in SUM159 cells having the 
mutant reporter. We observed low luciferase activity and loss of knockdown effect in 
the cells having Mut1 construct (Fig. 4H, S5D), suggesting that site1 is the response site 
for NKX6.1. In Mut2 construct, luciferase activity was significantly reduced in NKX6.1 
knockdown (Fig. 4H). This result indicates that NKX6.1 does not work on this site. 
To verify that NKX6.1 binds to the sequence of site1, we carried out EMSA 
and DNA pull-down assay. We used the wild type and mutated DNA fragments shown 
in Table S3. In EMSA, we detected a shifted band in wild type fragments, while no 
band was observed at the same position in the mutated fragments (Fig. S5E, arrow), 
indicating that a DNA-protein complex is formed at that sequence. To determine 
whether NKX6.1 participates in this DNA-protein complex, we performed pull-down 
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assay and detected NKX6.1 binding. We observed NKX6.1 binding in wild type 
fragments, but not in the mutated fragments (Fig. S5F). This is consistent with the 
results of promoter assay and EMSA, and strongly suggests that NKX6.1 binds to the 
sequence to up-regulate IL6 expression. 
 
3.5 The NKX6.1 - IL-6 network regulates cell growth 
In basal-like breast cancer cell lines, loss of NKX6.1 function reduces IL6 expression 
and cell growth. We performed rescue experiments to investigate whether the reduced 
cell growth is caused by the reduction in IL6 expression. We established cells with 
forced expression of IL-6-FLAG, and used FLAG expression as a control. The increase 
in levels of IL-6 in the IL-6-FLAG expressing cells was confirmed by immunoblotting 
on supernatant (Fig. 5A, B). The reduction in pSTAT3 levels that occurred as a result of 
loss of NKX6.1 function was reversed in the IL-6-FLAG expressing cells (Fig. 5C,D). 
There was no significant difference between the growth of cells with forced 
FLAG- and IL-6-FLAG expression in shGFP or crGFP cells, which featured normal 
NKX6.1 expression (Fig. 5E,F). This suggests that these cells have a maximum level of 
growth activity and that additional IL-6 was not able to enhance their growth beyond 
this. Cell number was reduced in the FLAG-expressing cells as a result of loss of 
NKX6.1 function. This reduction was recovered by exogenous IL-6 expression. This 
indicates that the NKX6.1 - IL-6 network up-regulates cell growth in basal-like breast 
cancer cell lines. 
Next, we used PCNA staining to determine whether the cell growth recovery by 
exogenous IL-6 expression is caused by a restoration of cell proliferation ability (Fig. 
S6). In shGFP or crGFP cells, there was no significant difference in the PCNA-positive 
percentage between cells with FLAG- or IL-6-FLAG expression. In NKX6.1-depleted 
cells, reduced cell proliferation was observed, and this reduction was recovered by 
exogenous IL-6 expression (Fig. S6). This supports the notion that NKX6.1 promotes 
cell proliferation through IL-6 up-regulation. 
 
3.6 NKX6.1 is required for tumor formation 
To investigate the regulation of cell growth by the NKX6.1 - IL-6 network in vivo, we 
performed xenograft experiments with SUM159 cells. Cells were transplanted into the 
fat-pad of six-week-old female NOD/SCID mice. We analyzed tumor formation four 
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weeks after transplantation. In the FLAG-expressing control group, shGFP cells showed 
tumors at all the points where they had been transplanted (Fig. 6A). However, there was 
a drastic reduction in the tumor formation rate in shNKX6.1 cells, indicating that 
NKX6.1 is required for tumor formation. Because most of the shNKX6.1 cell 
transplants showed no tumor formation, we were not able to compare size difference of 
tumor size between the tumors of shGFP control and shNKX6.1 cells. 
We next assessed the extent of restoration of this reduced tumor formation rate 
as a result of IL-6 forced expression. However, the reduced tumor formation capacity of 
the shNKX6.1 cells was not restored by IL-6-FLAG expression (Fig. 6A–C). This 
indicates that IL-6 expression alone is insufficient to restore the loss of NKX6.1 
function in tumor formation. 
 
3.7 A negative feedback loop in the NKX6.1 - IL-6 network 
Our results showed that NKX6.1 controls tumor formation and cell growth. The 
NKX6.1 - IL-6 network plays a role in NKX6.1-regulated cell growth. Some molecular 
events are known to have positive or negative feedback loops. If there is such a 
feedback loop in the NKX6.1 - IL-6 network, IL6 expression might either promote or 
suppress NKX6.1 expression. To address this, we analyzed whether NKX6.1 expression 
is affected by IL-6 knockdown, using the previously established shRNA-mediated IL-6 
knockdown system [22, 23]. The qRT-PCR analysis showed that NKX6.1 expression 
was increased as a result of IL-6 knockdown (Fig. 7A). Since IL-6 signaling activates 
the JAK2/STAT3 pathway and pSTAT3 regulates gene expression [24], we established 
an shRNA-mediated STAT3 knockdown system, and examined whether the NKX6.1 
level was increased by STAT3 knockdown. NKX6.1 expression was significantly 
up-regulated by STAT3 knockdown (Fig. 7B). These indicates that there is a negative 
feedback loop in the NKX6.1 - IL-6 network (Fig. 7C). 
To investigate whether NKX6.1 regulates IL6 expression in other types of 
cancer, we used two colon cancer cell lines, HCT116 and LoVo, and analyzed IL6 
mRNA levels in shGFP and shNKX6.1 groups. In the HCT116 cells, there was no 
detectable IL6 expression. IL6 was expressed in the LoVo cells, but the mRNA level 
was not affected by NKX6.1 knockdown (Fig. S7). This indicates that NKX6.1 does not 
regulate IL-6 expression in colon cancer. 
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3.8 Clinical significance of NKX6.1 in breast cancer 
We analyzed the relationship between NKX6.1 expression and prognosis using the 
SurvExpress platform [39]. Cohort studies on invasive breast cancer have shown that 
high NKX6.1 expression is associated with poor clinical outcome (Fig. S8) [40, 41]. 




Since the molecular properties of different types of cancer vary, studies that characterize 
a particular type contribute towards both understanding of that type and the 
establishment of a specific targeted therapy for it. In this study, we observed 
up-regulation of NKX6.1 expression in basal-like breast cancer and direct regulation of 
IL6 expression by NKX6.1. This NKX6.1 - IL-6 network promotes cell growth in 
basal-like breast cancer cells. We also found that NKX6.1 is required for tumor 
formation in xenografted cells. This indicates that NKX6.1 is one of the factors for 
malignancy in basal-like breast cancer. 
NKX factors are known to be developmental transcription factors. In the 
embryonic stages, NKX6.1 expression has been reported in the central nervous system 
[42-44], gut [44], and pancreas [45]. NKX6.1 is also expressed in the adult pancreas 
[46]. In the developing nervous system, it acts as a factor for ventral neural patterning 
during generation of motor and V2 neurons [38, 47]. Loss of NKX6.1 function affects 
astrocyte migration and differentiation, and reduces expression of a fibrous astrocyte 
marker and a regulator for white matter astrocyte development [48]. In the pancreas, 
NKX6.1 maintains the population of beta cells [46, 49]. A study based on conditional 
forced expression and a knockout system showed that NKX6.1 is required for beta cell 
differentiation from endocrine precursor cells [50]. Conditional knockout of NKX6.1 in 
mature beta cells results in conversion to delta cells, which indicates that it functions to 
maintain the beta cell character [50]. In pancreatic beta cells, NKX6.1 regulates 
expression of genes for insulin production and secretion [51], glucose uptake [51], and 
cell proliferation [52]. It also positively regulates NKX6.1 gene expression in pancreatic 
beta cells, but not in fibroblasts [38]. The different roles of NKX6.1 among neurons, 
glial cells and pancreatic beta cells suggest that its function is modified in a 
cell-type-dependent manner. 
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A recent study has shown that NKX6.1 suppresses cervical cancer metastasis 
[19]. In cervical cancer cell lines, ectopic NKX6.1 represses expression of the 
mesenchymal marker gene VIM by recruiting a chromatin-remodeling factor, BAF155. 
At the same time, NKX6.1 recruits another chromatin-remodeling factor, RBBP7, to 
activate expression of the CDH1 gene that encodes a cell-cell adhesion molecule. We 
analyzed the function of NKX6.1 in basal-like breast cancer that expresses 
mesenchymal marker genes. We found that NKX6.1 expression was high in basal-like 
breast cancer, and loss of NKX6.1 function did not significantly affect expression of 
epithelial or mesenchymal marker genes. This suggests that NKX6.1 is not involved in 
preservation of the mesenchymal character in basal-like breast cancer. Given that the 
function of NKX6.1 varies among cell types in normal cells, functional divergence in 
cancer cells is likely to be the result of differences between cancer types. In support of 
this hypothesis, the NKX6.1 - IL-6 network exists in basal-like breast cancer but not in 
colon cancer. This study has therefore revealed the function of NKX6.1 in basal-like 
breast cancer only. 
IL-6 is a signaling protein that is involved in cell growth in breast cancer, and is 
strongly expressed in basal-like breast cancer [22, 28]. This study revealed a part of the 
regulatory mechanism of IL6 expression in basal-like breast cancer cells. Previously, 
several studies have investigated the regulators of IL6 expression in various cell types. 
In T cells, RELA/p65 activates IL6 promoter [53]. IL6 expression is activated by 
RELA/p65 introduction and by RELA/p65 and C/EBP co-introduction in luminal breast 
cancer and osteosarcoma, respectively, and this is impaired by administration of 
17beta-estradiol [54]. A study based on renal mesangial cells revealed that IL6 
expression is regulated by the transcription factors AP-1, CREB, C/EBP and RELA/p65 
[55]. A small GTPase Rac1 activates RELA/p65, which results in up-regulation of IL6 
expression and activation of IL-6 signaling [56]. In B cells, C/EBP, AP-1 and 
RELA/p65 are involved in IL6 expression [57]. In HeLa cells, IL6 promoter activity 
was stimulated by a dominant negative c-Jun transcription factor, as well as by C/EBP 
and RELA/p65 [58]. Notch signaling serves as an activator for IL6 expression in 
macrophages [59]. In this study, we discovered that NKX6.1 up-regulates IL6 
expression in basal-like breast cancer. We identified the response region to NKX6.1 in 
IL6 promoter. Our pull-down assay showed that NKX6.1 possesses a binding potential 
to the identified region of IL6 promoter implying that NKX6.1 directly regulates IL6 
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expression. These findings characterize NKX6.1 as an IL6 regulator, which might 
provide novel insights into IL6 regulation in basal-like breast cancer cells. 
Basal-like breast cancer is heterogenous, and we previously reported that IL6 
expressing cells promotes growth of IL6 negative cells [23]. That suggests that if a 
small population of cells acquires NKX6.1 expression in a cancer tissue, these cells 
activate cell growth of surrounding cancer cells via IL-6 expression. Therefore, 
prevention of NKX6.1 function might be one of therapeutic strategies for basal-like 
breast cancer. 
 Publicly available clinical data for invasive breast cancer have shown that 
NKX6.1-high patients have poor clinical outcome. If a therapy targeting NKX6.1 
function is established, it will be used to care such patients. However, loss of NKX6.1 
function affects pancreatic beta cell function and maintenance, and causes cervical 
cancer metastasis. Therefore, approaches for avoidance of undesirable effects, such as 
drug delivery system to breast cancer, would be required in NKX6.1-targeted therapy. 
In this study, we analyzed the NKX6.1 function in basal-like breast cancer. 
NKX6.1 binds to the IL6 promoter region and up-regulates the IL6 expression, which 
results in the promotion of IL-6 signaling and cell growth. In addition, the results of our 
knockdown experiment for IL-6 expression imply that IL-6 signaling down-regulates 
NKX6.1 expression. This negative feedback loop could function to tune the NKX6.1 
expression level and the activity of the downstream factors of NKX6.1. Furthermore, 
we observed the loss of tumor formation ability in NKX6.1-depleted cells. The 
mechanisms for mammary tumorigenesis regulation are complex, involving both 
tumor-intrinsic and -extrinsic factors. The activation of proto-oncogenes and oncogenic 
signaling pathways are crucial intrinsic factors in tumor formation and progression. In 
the tumor microenvironment, tumor cells develop tumor stroma, endothelial cells, 
cancer-associated fibroblasts, and bone marrow-derived cells, which are considered the 
principle determinants of tumor progression. These factors work together to regulate 
tumor formation and progression. Although in vitro studies have shown that IL-6 
signaling promotes basal-like breast cancer cell growth and expands tumor-initiating 
breast cancer cells [22, 23], the role of IL-6 in mammary tumorigenesis is still unclear. 
Here, we observed the loss of tumor formation ability in NKX6.1-depleted cells. 
Exogenous IL-6 expression proved unable to recover this ability, although it restored 
the reduced cell growth of NKX6.1-depleted cells. This suggests that the 
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NKX6.1-regulated tumor formation ability requires the orchestrated interaction of 
several factors, and that IL-6 signaling alone is insufficient for tumor formation. It also 





Embryonic and cancer cells share several cellular properties, such as proliferation, 
motility and stemness. During embryonic development, accurate regulation of 
transcription factors is required for cells to differentiate into proper states, and 
inappropriate expression of transcription factors could lead to failure in differentiation 
or loss of cell identity and function. In cancer cells, up-regulation of embryonic 
transcription factors alters gene expression, which promotes tumor cell growth, survival 
and motility, as well as changes in cell state, such as epithelial-mesenchymal transitions. 
In this study, we found that the NKX6.1 homeobox transcription factor is up-regulated 
in basal-like breast cancer. Furthermore, we showed that NKX6.1 directly regulates IL6 
expression and promotes cell growth via the NKX6.1 - IL-6 network. This study 
improves our understanding of basal-like breast cancer and contributes to the 
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Fig. 1. Expression of NKX factors in breast cancer cell lines. (A-E) Quantification of 
expression levels of NKX1.2 (A), NKX2.1 (B), NKX2.8 (C), NKX3.1 (D), and NKX6.1 
(E) in breast cancer cell lines. Value of MCF-7 cells was set as 1. Gray bars represent 
basal-like breast cancer cell lines. (F) Immunoblotting shows that NKX6.1 signals were 
detected in basal-like breast cancer cell lines SUM159 and MDA-MB-231, but not 
detected in MCF10A. MCF-7 and T-47D cells. Anti-beta actin antibody was used as an 
internal control. (G-K) Immunostaining were performed to detect NKX6.1 expression in 
MCF10A (G), MCF-7 (H), T-47D (I), SUM159 (J), and MDA-MB-231 (K). Nuclei 
were visualized by Hoechst 33342 (G’-K’). n.d.: not detected. Student’s t-test was used 
to analyze significance. *: P < 0.05, **: P < 0.01. Error bars represent the standard 
deviation. Scale bars indicate 100 μm. 
 
Fig. 2. Loss of NKX6.1 function affects cell growth in basal-like breast cancer cells. 
(A) Treatment with shRNA for NKX6.1 reduced the NKX6.1 mRNA level in SUM159 
and MDA-MB-231 cells. (B) Immunoblotting showed reduction in NKX6.1 protein 
level in knockdown cells. (C,D) Cell growth was reduced in cells expressing shNKX6.1 
in both SUM159 (C) and MDA-MB-231 cells (D). Cell number was counted manually 
at day 4. (E) Immunoblotting revealed the effect of CRISPR/Cas9-mediated NKX6.1 
knockout: a truncated NKX6.1 signal was apparent in crNKX6.1 cells. (F) Cell growth 
was reduced in NKX6.1-knockout MDA-MB-231 cells. Cell number was counted 
manually at day 4. (G, H) Ratio of PCNA-positive cells in NKX6.1 knockdown (G) and 
knockout cells (H). Student’s t-test was used to analyze significance. *: P < 0.05, **: P 
< 0.01. Error bars represent the standard deviations. 
 
Fig. 3. NKX6.1 positively regulates IL6 expression. (A,B) Relative IL6 mRNA level 
following NKX6.1 knockdown (A) and knockout cells (B) was analyzed by qRT-PCR. 
(C-F) Immunostaining analysis of levels of pSTAT3, a marker of IL-6 signaling, in 
SUM159 and MDA-MB-231 cells. Both shGFP (control; C,E) and shNKX6.1 (D,F) 
cells were analyzed. Nuclei were visualized by Hoechst 33342 (C’-F’). (G) 
Immunoblotting was performed to analyze protein levels of pSTAT3, STAT3, and 
NKX6.1. pSTAT3 signal was reduced following NKX6.1 knockdown without changes 
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in total STAT3 amount. Student’s t-test was used to analyze significance. *: P < 0.05, 
**: P < 0.01. Error bars represent the standard deviations. Scale bars indicate 100 μm. 
 
Fig. 4. NKX6.1 activates IL6 promoter. (A,B) Relative luciferase activities to minimal 
promoter are shown. Values were obtained from the same data shown in Supplementary 
Fig. S5. (C) A pull-down assay with IL6 promoter oligos was performed to analyze the 
binding potential of NKX6.1 to IL6 promoter region. Protein lysate was obtained from 
SUM159 culture. (D) Competition assay with the proximal 100bp, 50bp, and 20bp 
fragments was performed. (E, F) ChIP assay of SUM159 cells having forced expression 
of FLAG or NKX6.1-FLAG protein was performed. Enrichment of IL6 promoter region 
was analyzed by quantitative PCR (E) and regular PCR (F). (G) DNA sequence of the 
region between 50 bp and 20 bp is shown. Underlines indicate candidate sites for 
NKX6.1-regulated IL6 expression. Bold letters indicate mutations. (H) Relative 
luciferase activity of cells having mutant construct is shown. Student’s t-test was used 
to analyze significance. **: P < 0.01. Error bars represent the standard deviations. 
 
Fig. 5. The NKX6.1 - IL-6 network regulates cell growth in basal-like breast cancer. 
(A,B) Immunoblotting on supernatant samples shows secreted IL-6-FLAG protein in 
SUM159 (A) and MDA-MB-231 cells (B). FLAG expression vector was used as a 
control. (C,D) Immunoblotting showed the restoration of the reduced pSTAT3 level of 
NKX6.1-depleted cells by IL-6-FLAG expression. (E,F) Cell growth assay was 
performed in the control and IL-6-FLAG expressing cells. Cell number was counted 
manually at day 4. In both SUM159 (E) and MDA-MB-231 cells (F), the reduced cell 
growth was recovered by IL6 forced expression. Student’s t-test was used to analyze 
significance. *: P < 0.05, **: P < 0.01. Error bars represent the standard deviations. 
 
Fig. 6. NKX6.1 is required for tumor formation. (A) Tumor formation rate is 
presented. SUM159 cells were injected into the fat-pad of 6-week-old female 
NOD/SCID mice. Four weeks after transplantation, tumor formation was assessed. 
Fisher’s exact test was used to analyze significance. (B,C) Typical images of tumor 
formation. Tumors were observed at the point where IL-6-FLAG;shGFP cells were 
transplanted (B), but not where IL-6-FLAG;shNKX6.1 cells were transplanted (C). 
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Fig. 7. Negative feedback loop in the NKX6.1 - IL-6 network. (A) Relative mRNA 
levels of NKX6.1 in IL-6 knockdown cells are graphed. (B) Relative mRNA levels of 
NKX6.1 in STAT3 knockdown cells are graphed. The NKX6.1 expression was increased 
by STAT3 knockdown in SUM159 and MDA-MB-231 cells. (C) Schematic diagram of 
the role of NKX6.1 in basal-like breast cancer. Student’s t-test was used to analyze 










A homeobox protein, NKX6-1, up-regulates interleukin-6 expression for cell 
growth in basal-like breast cancer cells 
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Fig. S1. The NKX6.1 expression was up-regulated in the patient with basal-like 
breast cancer. Data was obtained from GSE3744, and analyzed on Gene Expression 
Omnibus platform. Mann-Whitney U-test was used to analyze significance. *: P < 0.05. 



































Fig. S2. Truncated NKX6.1 is distributed to cytoplasm. (A-D) Immunostaining with 
anti-FLAG M2 antibody were performed in SUM159 (A, B) and MDA-MB-231 cells 
(C, D) having NKX6.1-FLAG or Truncated NKX6.1-FLAG expression. Nuclei were 













Fig. S3. Cell survival was reduced by shNKX6.1 expression, but not by NKX6.1 
knockout. (A,B) Ratios of TUNEL-positive cells were analyzed in cells with 
shRNA-medicated NKX6.1 knockdown (A) and with CRISPR/Cas9-mediated NKX6.1 






















































































Fig. S4. The expression of mesenchymal markers is not regulated by NKX6.1 in 
basal-like breast cancer. (A,B) Quantification of the mRNA levels for a mesenchymal 
marker VIM is shown. SUM159 (A) and MDA-MB-231 cells (B) were used. (C,D) 
Quantification of the mRNA levels for a mesenchymal marker CDH2 is shown. 
SUM159 (C) and MDA-MB-231 cells (D) were used. No significant difference was 
observed between the control and NKX6.1-depleted cells. Student’s t-test was used to 
































































































Fig. S5. NKX6.1 activates IL6 promoter. (A) Construct of IL6 promoter reporter. 
(B,C) Graphs of the raw data of reporter assay are shown. SUM159 (B) and 
MDA-MB-231 cells (C) were used. (D) Graph of the raw data of mutant construct with 
or without NKX6.1 knoxkdown. Error bars represent the standard deviations. 
(E) EMSA shows a shifted band (arrow). The band was not seen when DNA 
oligo has a mutation shown in Fig. 4G Mut1. (F) Pull-down assay shows 

























































































































































































+     +     −     −     Control Oligo!
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Fig. S6. The NKX6.1 - IL-6 network promotes cell proliferation. (A,B) Ratios of 
PCNA-positive cells were analyzed in IL-6 forced expression cell lines. Restoration of 




























































Fig. S7. NKX6.1 knockdown does not regulate the IL6 expression in a colon cancer 
cell line, LoVo. (A) qRT-PCR assay showed the efficiency of NKX6.1 knockdown in 
LoVo cells. (B) Quantification of IL6 mRNA level following NKX6.1 knockdown in 
LoVo cells. The result shows no significant difference from the control group. Student’s 














Fig. S8. Relation between NKX6.1 mRNA level and prognosis in the patients with 
invasive breast cancer. (A,B) Survival curves were depicted based on the data from 
two cohort studies which are publicly available. Data were analyzed by SurvExpress 
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Table S1. Sequences of qRT-PCR primers. 
Gene Primer Sequence (5’à  3’) 
EF1A1 EF1A1_F AAATGACCCACCAATGGAAGCAGC EF1A1_R TGAGCCGTGTGGCAATCCAATACA 
NKX1.1 NKX1.1_F ACGACACCAACGGCTACAG 
NKX1.1_R CGCTTCGTCCTCGTCGTC 
NKX1.2 NKX1.2_F GGAAAGATGCCAGCTCCAG NKX1.2_R CGCATCCTCCTCCTCTTCCG 
NKX2.1 NKX2.1_F CAACCTGGGCAACATGAGC 
NKX2.1_R CCCATGAAGCGGGAGATG 
NKX2.2 NKX2.2_F CCTTCTACGACAGCAGCGA NKX2.2_R CTTGGAGCTTGAGTCCTGAG 
NKX2.3 NKX2.3_F CTATGTCCACACGGTCCTG 
NKX2.3_R AGTCTCCGGCCGTCTCTA 
NKX2.4 NKX2.4_F GGCAACATGGGCGAGCTG NKX2.4_R TGAACCTGGAGATTGACGAGTAG 
NKX2.5 NKX2.5_F TTCTATCCACGTGCCTACAG 
NKX2.5_R GTTGTCCGCCTCTGTCTTC 
NKX2.6 NKX2.6_F GAGGGTCAGAGGTTCACAA NKX2.6_R CATCTCCAAGACTGCCTCAC 
NKX2.8 NKX2.8_F CTAGATTTACCCGAGCAGGAC 
NKX2.8_R GGTCTCCAGGCTGCTCTC 
NKX3.1 NKX3.1_F GCAGAGACCGAGCCAGAAA NKX3.1_R GCTTCTGCGGCTGCTTAG 
NKX3.2 NKX3.2_F GCCGCTTCCAAAGACCTAGA 
NKX3.2_R GCCAACACCGTCGTCCTC 
NKX6.1 NKX6.1_F GGGCTCGTTTGGCCTATTC NKX6.1_R CGTGCTTCTTCCTCCACTTG 
NKX6.2 NKX6.2_F CGAGAGCCAGGTGAAGGT 
NKX6.2_R CCGAGTCCTGCTTCTTCTTG 
NKX6.3 NKX6.3_F GGAAGAAGCAGACACTCCTG NKX6.3_R GCTCTTCTTCCGCCACTTG 
CDH1 CDH1_F TTGCAAATTCCTGCCATTCT 
 CDH1_R TCCTCCGAAGAAACAGCAAG 
 VIM VIM_F TCTGGATTCACTCCCTCTGG 
 VIM_R TCAAGGTCATCGTGATGCTG 
 CDH2 CDH2_F GACAATGCCCCTCAAGTGTT 
 CDH2_R CCATTAAGCCGAGTGATGGT 
 IL6 IL6_F GACAGCCACTCACCTCTTC 
 IL6_R TGCTTTCACACATGTTACTCTTG 
 IL6 promoter 
IL6-pro_F AAAGGACGTCACATTGCAC 
IL6-pro_R ACTCTAATATTGAGACTCATGGGAA 
Table S2. Sequences of shRNAs. 








Table S3. Sequences of oligos for EMSA 
Oligo  Sequence (5’à  3’) 
EMSA wild type CTCCAACAAAGATTTATCAAATGTG 




















CSF3 -5.168  +
CXCL8 -2.794  +
IL1B -2.446  +  +
IL6 -2.291  +  +  +
EREG -2.183  +  +  +
CDCA7L -2.121  +
SOD2 -2.056  +
RBPJ -2.014  +  +
DHRS2 -1.996  +
IL7R -1.967  +
XDH -1.759  +
HMGA1 -1.759  +
LIF -1.672  +  +
MTBP -1.605  +
KRT6A -1.604  +
IL1A -1.489  +  +
NKX6-1 -1.482  +
EPGN -1.421  +
TGFA -1.419  +  +
ICOSLG -1.393  +
BLM -1.375  +
EGR1 -1.307  +  +
CDK2 -1.305  +
PRDX1 -1.245  +
ETV4 -1.235  +
BUB1 -1.224  +
KIF15 -1.223  +
CENPF -1.217  +
AKR1C2 -1.213  +
TTK -1.212  +
XRCC4 -1.207  +
CCNB1 -1.181  +
MYH10 -1.178  +
CNOT11 -1.171  +
FERMT1 -1.171  +
NAMPT -1.140  +
UTP20 -1.134  +
CXCL1 -1.131  +  +
FER -1.131  +  +
TFAP4 -1.121  +
ASPM -1.113  +  +
BIRC5 -1.111  +
BNC1 -1.095  +
BCAT1 -1.089  +
RBP4 -1.076  +
CDC7 -1.070  +
BUB1B -1.063  +
SLIT2 -1.063  +
IGFBP4 -1.058  +
EFNB1 -1.058  +
PA2G4 -1.056  +
RAF1 -1.048  +  +
HELLS -1.042  +
DLGAP5 -1.042  +
UHRF1 -1.033  +
F3 -1.032  +
NASP -1.028  +
MKI67 -1.027  +
CDC6 -1.019  +
SOX7 -1.006  +
Increased by shNKX6.1
CRLF1 4.011  +
GAL 3.308  +
IFIT3 2.902  +
SPRY1 2.837  +
PTN 2.667  +
APOE 2.590  +
WNT5A 2.496  +  +  +
VIPR1 2.390  +
ADRA1B 2.328  +
IGFBP2 2.314  +
MMP14 2.268  +
ITGA1 2.190  +
NOTCH3 2.166  +
CSPG4 2.069  +
GAS1 1.933  +  +
KAT2B 1.930  +
CRIP2 1.919  +
HCLS1 1.896  +
EBI3 1.892  +
IGFBP3 1.847  +  +
LEPREL2 1.845  +
MXD4 1.750  +
KDR 1.722  +
ING4 1.665  +
CCL5 1.650  +
SPEG 1.624  +
PDGFRB 1.615  +  +
CTGF 1.596  +  +
LIPA 1.591  +
GATA3 1.548  +
TIMP2 1.542  +
EDN2 1.535  +
CDKN2D 1.534  +
GRN 1.514  +
TRPM4 1.479  +
CD40 1.468  +  +
ROS1 1.455  +
MAGED1 1.447  +
TNFSF12 1.442  +
CDKN1C 1.441  +
GNG2 1.426  +
COL18A1 1.383  +  +
NMB 1.381  +
DDR1 1.372  +
ECM1 1.367  +
TGFBI 1.352  +
SMAD6 1.329  +
CYP27B1 1.298  +
BTG1 1.288  +
PPAP2A 1.254  +
INSIG1 1.251  +
ID2 1.244  +  +  +
RHBDF1 1.235  +
TP53INP1 1.231  +
PTPRK 1.224  +
NUPR1 1.201  +
CLEC11A 1.199  +
CDK5 1.179  +
POLD4 1.158  +
LOXL2 1.157  +
ITGAV 1.139  +
CDKN1B 1.137  +  +
CYR61 1.131  +  +
FZD6 1.128  +
EMX2 1.096  +
ANG 1.065  +  +
IFITM1 1.061  +
NRG1 1.057  +  +
IGFBP7 1.054  +
DYNAP 1.049  +
NCSTN 1.047  +
GAS6 1.039  +  +
AXIN2 1.034  +  +
PKD2 1.024  +
ITGB1 1.016  +  +
CTNNBIP1 1.014  +
1Gene ontology number is GO:0008283 Cell proliferation
2Gene ontology number is GO:0008284 Positive for cell proliferation
3Gene ontology number is GO:0008285 Negative for cell proliferation
